Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring.
Aged
Biomarkers
/ metabolism
Blood Glucose
/ analysis
Blood Glucose Self-Monitoring
Diabetes Mellitus, Type 2
/ metabolism
Glycated Hemoglobin
/ analysis
Humans
Hyperglycemia
/ epidemiology
Hypoglycemia
/ epidemiology
Incidence
Insulin Secretion
Japan
/ epidemiology
Male
Middle Aged
Prospective Studies
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 04 2021
27 04 2021
Historique:
received:
16
01
2021
accepted:
06
04
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
15
10
2021
Statut:
epublish
Résumé
The contribution of endogenous insulin secretion to glycemic variability (GV) may differ between patients with impaired insulin secretion and those with preserved secretion. Our objective was to determine the linearity of the relationship between fasting C-peptide (CPR) as a marker of endogenous insulin secretion and GV in type 2 diabetes (T2DM), regardless of the type of antidiabetic treatment. We conducted a prospective observational study using continuous glucose monitoring obtained from 284 Japanese outpatients with T2DM with various HbA1c values and antidiabetic treatment. We constructed a prediction curve of base-line CPR versus coefficient of variation (CV) and identified the clinical factors associated with CV using multiple regression analysis. Fasting CPR showed a significant negative log-linear relationship with CV (P < 0.0001), and the latter being strikingly high in the low-CPR group. The multiple regression analysis showed that low CPR was an independent predictor of high CV (P < 0.0001). The significant correlations were sustained in both patients with/without insulin treatment. The contribution of endogenous insulin secretion to GV depends on the extent of insulin secretion impairment. Fasting CPR may represent a useful indicator of GV instability in T2DM.
Identifiants
pubmed: 33907279
doi: 10.1038/s41598-021-88749-9
pii: 10.1038/s41598-021-88749-9
pmc: PMC8079412
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Glycated Hemoglobin A
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
9057Références
Arch Intern Med. 1999 Feb 8;159(3):281-4
pubmed: 9989540
Diabetol Int. 2020 Jul 24;11(3):165-223
pubmed: 32802702
J Diabetes Investig. 2011 Aug 2;2(4):297-303
pubmed: 24843502
Diabetes Res Clin Pract. 2014 May;104(2):266-72
pubmed: 24630619
Circ J. 2016;80(1):202-10
pubmed: 26511357
Cardiovasc Diabetol. 2015 Jun 04;14:70
pubmed: 26041130
Diabetes Care. 2009 Jun;32(6):1058-62
pubmed: 19244086
Diabetes Technol Ther. 2020 Jul;22(7):492-500
pubmed: 31886733
Diabetologia. 2020 May;63(5):906-914
pubmed: 32034440
Diabetes Technol Ther. 2012 Oct;14(10):868-76
pubmed: 22953755
Diabetes Res Clin Pract. 2019 Dec;158:107904
pubmed: 31672500
Diabetes Care. 2018 Nov;41(11):2370-2376
pubmed: 30201847
Diabetes. 1995 Nov;44(11):1249-58
pubmed: 7589820
Diabetes Metab. 2020 Feb;46(1):61-65
pubmed: 30796973
Diabetes. 2014 Feb;63(2):739-48
pubmed: 24089509
Diabetes. 1988 Jan;37(1):81-8
pubmed: 3275557
Acta Diabetol. 2018 Aug;55(8):877-880
pubmed: 29651558
Nat Rev Endocrinol. 2017 Jul;13(7):425-436
pubmed: 28304392
Diabetes Technol Ther. 2015 Nov;17(11):787-94
pubmed: 26171659
Diabetes Obes Metab. 2018 Sep;20(9):2274-2281
pubmed: 29770541
Diabetes Care. 2017 Feb;40(2):194-200
pubmed: 27913575
Diabetes. 1970 Sep;19(9):644-55
pubmed: 5469118
Diabetes Care. 2017 Dec;40(12):1631-1640
pubmed: 29162583
Clin Chim Acta. 2016 Oct 1;461:146-50
pubmed: 27502250
Diabetol Metab Syndr. 2020 Mar 16;12:22
pubmed: 32190124
J Diabetes Sci Technol. 2015 Aug 14;10(1):50-9
pubmed: 26275643
J Diabetes Investig. 2020 Oct 6;:
pubmed: 33021063
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185